Page last updated: 2024-12-11
bromotetrandrine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bromotetrandrine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9831563 |
| SCHEMBL ID | 16254206 |
| MeSH ID | M0503949 |
Synonyms (14)
| Synonym |
|---|
| bromotetrandrine |
| w-198 |
| 5-bromotetrandrine |
| SCHEMBL16254206 |
| v3orv27yjy , |
| 62067-29-2 |
| unii-v3orv27yjy |
| (4as,16as)-20-bromo-3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline |
| 16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline, 20-bromo-3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4as,16as)- |
| h-1.3 |
| (1s,14s)-19-bromo-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18(33),19,21,24,26,31-dodecaene |
| (11s,31s)-35-bromo-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane |
| DTXSID901026509 |
| AKOS040748062 |
Research Excerpts
Overview
5-Bromotetrandrine (Br-Tet) is a newly synthesized brominated derivative of Tet.
| Excerpt | Reference | Relevance |
|---|---|---|
| "5-Bromotetrandrine (Br-Tet) is a newly synthesized brominated derivative of Tet." | ( Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X, 2009) | 1.16 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " No serious or severe adverse events were found in the study." | ( Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. Li, ZY; Qing, YP; Wang, FP; Wang, Y; Xu, N; Yu, Q; Zheng, L, 2010) | 0.65 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "A rapid and sensitive liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for the determination of bromotetrandrine in rat plasma has been developed and applied to pharmacokinetic study in Sprague-Dawley (SD) rats after a single oral administration." | ( Liquid chromatographic/mass spectrometry assay of bromotetrandrine in rat plasma and its application to pharmacokinetic study. Li, Q; Liu, C; Song, N; Zhang, S, 2009) | 0.82 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "This study was aimed to investigate the reversal effect of 5-bromotetrandrine (5-BrTet) and magnetic nanoparticle of Fe(3)O(4) (Fe(3)O(4)-MNPs) combined with DNR in vivo." | ( Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine. Chen, BA; Chen, WJ; Cheng, J; Ding, JH; Gao, C; Gao, F; Li, GH; Li, XM; Liu, LJ; Sun, XC; Wang, XM; Wu, YN; Xu, WL, 2009) | 0.8 |
| " This study investigated the efficiency of novel multifunctional Fe(3)O(4) magnetic nanoparticles (Fe(3)O(4)-MNP) combined with chemotherapy and hyperthermia for overcoming multidrug resistance in an in vivo model of leukemia." | ( Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Bao, W; Cai, X; Chen, B; Cheng, J; Ding, J; Gao, C; Liu, R; Ren, Y; Song, H; Tian, L; Wang, J; Wang, L; Wang, S; Wang, X; Wu, W; Xia, G; Zhang, H, 2012) | 0.38 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The low oral bioavailability is a great challenge for oral formulation development." | ( Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer. Ding, R; Fu, Y; Gong, T; Li, H; Luo, J; Zhang, T; Zhang, Z, 2017) | 0.46 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "25 h and decreasing at 2 h after dosing in most tissues." | ( [Tissue distribution and excretion of bromotetrandrine in rats]. Liu, CX; Lu, R; Wang, FP; Wei, GL; Xiao, SH, 2005) | 0.6 |
| " The pharmacokinetics parameters of bromotetrandrine indicated that the compound was rapidly distributed and accumulated in the tissues, and slowly cleared from plasma, which supported the use of BrTet for a once or twice dosing per chemotherapy cycle." | ( Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. Li, ZY; Qing, YP; Wang, FP; Wang, Y; Xu, N; Yu, Q; Zheng, L, 2010) | 0.92 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.25) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.55%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (95.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||